MX2021012507A - Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona. - Google Patents

Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.

Info

Publication number
MX2021012507A
MX2021012507A MX2021012507A MX2021012507A MX2021012507A MX 2021012507 A MX2021012507 A MX 2021012507A MX 2021012507 A MX2021012507 A MX 2021012507A MX 2021012507 A MX2021012507 A MX 2021012507A MX 2021012507 A MX2021012507 A MX 2021012507A
Authority
MX
Mexico
Prior art keywords
dioxopiperidin
dione
fluoro
amino
methyl
Prior art date
Application number
MX2021012507A
Other languages
English (en)
Spanish (es)
Inventor
Antonia Lopez-Girona
Michael Pourdehnad
Rama Krishna Narla
Maria Soraya Carrancio Anton
Tonia J Buchholz
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2021012507A publication Critical patent/MX2021012507A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021012507A 2019-04-12 2020-04-09 Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona. MX2021012507A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962833432P 2019-04-12 2019-04-12
PCT/US2020/027358 WO2020210418A1 (en) 2019-04-12 2020-04-09 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione

Publications (1)

Publication Number Publication Date
MX2021012507A true MX2021012507A (es) 2022-01-24

Family

ID=70465546

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012507A MX2021012507A (es) 2019-04-12 2020-04-09 Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.

Country Status (26)

Country Link
US (3) US11390617B2 (https=)
EP (1) EP3952880B1 (https=)
JP (1) JP7562557B2 (https=)
KR (1) KR102944213B1 (https=)
CN (1) CN114144182B (https=)
AR (1) AR119715A1 (https=)
AU (1) AU2020270917B2 (https=)
BR (1) BR112021020372A2 (https=)
CA (1) CA3132538A1 (https=)
CL (1) CL2021002651A1 (https=)
DK (1) DK3952880T3 (https=)
ES (1) ES3061998T3 (https=)
FI (1) FI3952880T3 (https=)
HR (1) HRP20251668T1 (https=)
IL (1) IL287145A (https=)
LT (1) LT3952880T (https=)
MA (1) MA55608A (https=)
MX (1) MX2021012507A (https=)
PT (1) PT3952880T (https=)
RS (1) RS67593B1 (https=)
SG (1) SG11202111232RA (https=)
SI (1) SI3952880T1 (https=)
SM (1) SMT202600013T1 (https=)
TW (1) TWI853014B (https=)
WO (1) WO2020210418A1 (https=)
ZA (1) ZA202107668B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
AU2020369497B2 (en) 2019-10-21 2026-02-05 Celgene Corporation Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
US11666579B2 (en) * 2019-10-21 2023-06-06 Celgene Corporation Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CA3154890A1 (en) * 2019-10-21 2021-04-29 Maria Soraya Carrancio ANTON Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion
JP7676375B2 (ja) 2019-10-21 2025-05-14 セルジーン コーポレーション （ｓ）－２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンおよびその塩を含む固形体、並びにそれを含む組成物およびそれを使用する方法
WO2021080955A1 (en) 2019-10-21 2021-04-29 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CA3154908A1 (en) 2019-10-21 2021-04-29 Sreenivas S. Bhat Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam
AU2022252220A1 (en) * 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma
JP2024515108A (ja) * 2021-04-21 2024-04-04 セルジーン コーポレーション ２－（２，６－ジオキソピペリジン－３－イル）－４－（（２－フルオロ－４－（（３－モルホリノアゼチジン－１－イル）メチル）ベンジル）アミノ）イソインドリン－１，３－ジオンを使用して非ホジキンリンパ腫を治療する方法
EP4326266A1 (en) * 2021-04-21 2024-02-28 Celgene Corporation Methods of treating b-cell lymphoma using combination therapy
WO2022271557A1 (en) 2021-06-21 2022-12-29 Celgene Corporation Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002253795B2 (en) 2000-11-30 2007-02-01 The Children's Medical Center Corporation Synthesis of 4-Amino-Thalidomide enantiomers
PL2076260T3 (pl) * 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
EP2536706B1 (en) * 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
BR112015002285B1 (pt) * 2012-08-09 2022-05-10 Celgene Corporation Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer
HK1214552A1 (zh) 2012-11-05 2016-07-29 细胞基因公司 在腎損傷的受試者中用泊馬度胺治療癌症
CN105246480A (zh) * 2013-04-02 2016-01-13 细胞基因公司 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物
CN111205268B (zh) * 2014-10-30 2021-01-26 康朴生物医药技术（上海）有限公司 异吲哚啉衍生物、其中间体、制备方法、药物组合物及应用
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法
CN118344338A (zh) * 2018-04-23 2024-07-16 细胞基因公司 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途

Also Published As

Publication number Publication date
HRP20251668T1 (hr) 2026-02-27
US20240400548A1 (en) 2024-12-05
KR20210151895A (ko) 2021-12-14
CN114144182A (zh) 2022-03-04
CN114144182B (zh) 2024-05-24
FI3952880T3 (fi) 2026-02-05
LT3952880T (lt) 2026-01-26
US20220324855A1 (en) 2022-10-13
RS67593B1 (sr) 2026-01-30
CL2021002651A1 (es) 2022-04-29
BR112021020372A2 (pt) 2021-12-07
JP2022527398A (ja) 2022-06-01
KR102944213B1 (ko) 2026-03-26
US20200325129A1 (en) 2020-10-15
SI3952880T1 (sl) 2026-02-27
EP3952880B1 (en) 2025-12-10
US11390617B2 (en) 2022-07-19
CA3132538A1 (en) 2020-10-15
TWI853014B (zh) 2024-08-21
EP3952880A1 (en) 2022-02-16
JP7562557B2 (ja) 2024-10-07
WO2020210418A1 (en) 2020-10-15
SMT202600013T1 (it) 2026-03-09
AR119715A1 (es) 2022-01-05
DK3952880T3 (da) 2026-01-26
ES3061998T3 (en) 2026-04-08
ZA202107668B (en) 2025-01-29
TW202103705A (zh) 2021-02-01
IL287145A (en) 2021-12-01
AU2020270917B2 (en) 2025-08-28
PT3952880T (pt) 2026-02-17
US12103923B2 (en) 2024-10-01
SG11202111232RA (en) 2021-11-29
MA55608A (fr) 2022-02-16
AU2020270917A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
MX2021012507A (es) Metodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il)metil)bencil)amino)isoindolin-1,3-diona.
ZA201903125B (en) 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
MX2023014985A (es) Agonista del receptor de glp-1 y composicion y uso del mismo.
MX2020009454A (es) Desinfectante de superficies con propiedad biocida residual.
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
CR9716A (es) Bencimidazoles sustituidos como inhibidores de cinasa
ZA202204446B (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
CY1122290T1 (el) Παραγωγο 2-ακυλαμινοθειαζολιου για χρηση στην προληψη ή αντιμετωπιση νοσων της ουροδοχου κυστης/του ουροποιητικου συστηματος
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
CR10540A (es) Derivados ciclopropil amina
MX2021014357A (es) Metodos y formulaciones para tratar trastornos de la vision.
BR112022007417A2 (pt) Métodos de tratamento de malignidades hematológicas usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil) amino)isoindolina-1,3-diona
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
SG11201901617PA (en) Azole compound ophthalmic preparation
MX2023012294A (es) Metodos de tratamiento del linfoma no hodgkin mediante el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il) metil)benzil)amino)isoindolin-1,3-diona.
BR112022007150A2 (pt) Métodos de tratamento de leucemia linfocítica crônica usando 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoindolina-1,3-diona
MX2019005723A (es) Inhibidor del receptor del factor de crecimiento de fibroblastos 4 (fgfr4) y metodo de preparacion y uso del mismo.
EA201990480A1 (ru) Комбинация обратных агонистов гистамин-3 рецептора с ингибиторами ацетилхолинэстеразы
HK40066611A (en) Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
MX2023012911A (es) Metodos de tratamiento del mieloma multiple usando terapia combinada.
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.